Pleural Photodynamic Therapy for Pleural Malignancy

Open-label, single-arm trial of porfimer sodium in malignant mesothelioma and non-small cell lung cancer (NSCLC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Number of patients who received the entire multi-modality regimen at 2 years and Incidence of grade 4 or greater toxicity in the post-operative period as graded by the National Cancer Institute (NCI) CTCAE (Common Toxicity Criteria for Adverse Effects) version 4.0 at 90 days. Planned start Sep 2014; status: withdrawn.